Journal article Open Access

Griebel G, Holsboer F. Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? Nat Rev Drug Discov 11: 462-478

Griebel, Guy; Holsboer, Florian

The search for novel drugs for treating psychiatric disorders is driven by the growing medical need to improve on the effectiveness and side-effect profile of currently available therapies. Given the wealth of preclinical data supporting the role of neuropeptides in modulating behaviour, pharmaceutical companies have been attempting to target neuropeptide receptors for over two decades. However, clinical studies with synthetic neuropeptide ligands have been unable to confirm the promise predicted by studies in animal models. Here, we analyse preclinical and clinical results for neuropeptide receptor ligands that have been studied in clinical trials for psychiatric diseases, including agents that target the receptors for tachykinins, corticotropin-releasing factor, vasopressin and neurotensin, and suggest new ways to exploit the full potential of these candidate drugs.

Files (754.7 kB)
Name Size
article.pdf
md5:df8a434b52f7d22cf1e7cf67d188212a
754.7 kB Download
198
144
views
downloads
Views 198
Downloads 144
Data volume 108.7 MB
Unique views 193
Unique downloads 139

Share

Cite as